Our Mission

 

Energesis is developing novel therapeutics that produce efficacious and sustainable weight loss for patients with obesity. We are committed to combating the obesity epidemic with an approach addressing many of the unmet needs in the current marketplace.​

​​

​

Approach

 

From its origins, Energesis has been focused on the development of drugs to treat obesity and diabetes. Our novel approach, unlike appetite suppressants such as the GLP-1 drugs that reduce food intake, is to increase the body's energy expenditure. Our pipeline agents take advantage of the natural physiological properties of a type of fat cells known as brown adipocytes, or brown adipose tissue (BAT).

​

BAT is specialized in dissipating energy (from sugars and fats) as heat, normally serving 1) to produce heat in cold environments, and 2) as a “safety valve” to prevent excessive weight gain and the development of obesity. Individuals with obesity have been proven to have a lower amount of BAT than lean people, and our agents are designed to restore a normal, healthy amount of BAT in the obese. Moreover, in contrast to GLP-1 agonists and other incretin analogs, increasing the amount of BAT in people with obesity induces the body to defend a lower level of body weight and fat, enabling long-term weight maintenance.

 

Increasing BAT mass can be achieved by promoting - with a therapeutic drug - the recruitment of new brown fat cells from a reservoir of stem/progenitor cells found in all human adults. These progenitor cells were discovered by Energesis’ scientific co-founders and have formed the basis of the company’s discovery work. Our drug candidates that create new brown fat in this way demonstrate highly effective weight loss — all of which is from fat, without loss of lean muscle, and which is synergistic with the effects of the state-of-the-art GLP-1 agonists.

​

The Energesis management team brings a strong entrepreneurial record together with world-class scientific pharmaceutical, medical and product development expertise, and is working to develop a new generation of agents to effectively cure obesity.